Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.25 -3.09% 70.50 69.00 72.00 74.00 70.50 72.75 104,133 15:43:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.4 -0.8 -2.0 - 33

Ixico Share Discussion Threads

Showing 251 to 275 of 275 messages
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
06/11/2019
10:15
Added a few this morning with some IOF monies
volsung
05/11/2019
20:48
Better late than never - joined the party today
hatfullofsky
29/10/2019
12:18
The contract momentum continues to build for Aim-traded IXICO (IXI:73p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans – magnetic resonance imaging (MRI) and positron emission tomography (PET). Specifically, these scans provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. Having prompted analysts to materially upgrade their profit guidance not once, but twice since I first suggested buying the shares at 33p three months ago ('Alpha Report: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019), IXICO has just announced three new biopharma contracts, all of which highlight the value of its core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development. The first contract is focused on a Progressive Supranuclear Palsy (PSP) programme for a new client, ahead of patient enrolment later in 2019. The 12-month contract, worth £400,000, is expected to lead to a larger programme of work in early 2020, according to IXICO’s directors. The second contract is worth £350,000 over three years and is an expansion of a study with an existing client which will see IXICO’s AI-technology extended and deployed to qualify several sites in mainland China. The third contract involves IXICO providing imaging analytics services to support a Phase IV programme in mental health for a new US-based biotechnology client. It’s worth £450,000 over the next two years. Alongside news of the contract awards, IXICO has announced the appointment of a chief business officer, Lammert Albers. His commercial experience in clinical research organisations includes roles at US$6.5bn market capitalisation Nasdaq-listed corporation, PRA Health Sciences (PRAH), and latterly with Australian Stock Exchange quoted CogState (COG), during which time he has developed deep expertise of the Alzheimer's disease (AD) trials market. Based in the US, Mr Albers will have responsibility for global business development, with a particular focus in driving international growth in North America & Asia. It’s a sound strategic move which supports IXICO’s strategy of growth through international expansion. True, the shares have now increased in value by 118 per cent on an offer-to-bid basis since I initiated coverage 13 weeks ago, and are within pennies of hitting the upgraded 75p target price I outlined a fortnight ago (‘IXICO upgrades guidance again’, 15 October 2019). But with contract momentum building strongly, and profits from a relatively fixed cost base highly operationally geared to rising sales, then I see ample scope for outperformance against analyst estimates which conservatively suggest operating profits of £941,000 on revenue of £10.9m in the 2020/21 financial year. Moreover, the company’s net cash of £7.3m (15.5p a share) equates to 22 per cent of IXICO’s market capitalisation of £33.3m, so the business has substantial funding in place to support further contract wins. The earnings upgrade cycle looks to have some way to run and I am tweaking my target up from 75p to 85p. Trading on a bid-offer spread of 72p to 73p, I continue to rate IXICO’s shares a buy.
mirabeau
28/10/2019
14:19
IC today raised target price to 85p
29palms
28/10/2019
13:55
IC raised price target of 75p reached today which is way ahead of figs in December. Very bullish RNS this morning will help push this target price even higher IMHO
29palms
28/10/2019
07:09
IXICO announces client contracts and appointment of Chief Business Officer.
skinny
24/10/2019
10:34
Breakout to new high. As IC has stated share price price target raised to 75p ahead of figs early December. DYOR
29palms
21/10/2019
10:39
Bought a starter tranche this morning. Looking good
volsung
18/10/2019
18:11
Finished on 52 week highs, 70-80p next week. Great trading update, financial report early December. free stock charts from uk.advfn.com
ileeman
18/10/2019
10:47
IC has raised price target to 75p in run up to release of figs in early December. Looks like ready to breakout to new high. As always, DYOR
29palms
15/10/2019
11:46
Yes, excellent update. Missed opportunity to buy on drop at around 48p. Will hold for now...
johndoe23
15/10/2019
06:42
Trading Update for year ended 30 September 2019.
skinny
14/10/2019
11:17
Gradually moving up, should be a trading statement this month which is expected to be very positive
buying
16/9/2019
08:03
way oversold imo. Should be hitting new highs.
someuwin
04/9/2019
07:55
How unusual - an AIM placing doubles in a year. Wish they were all like this!
toffeeman
04/9/2019
07:15
Buyers about again.
someuwin
03/9/2019
13:48
Excellent breakout now and strong momentum. Good volume too. Directors bought in astutely not so long ago
aishah
03/9/2019
13:12
She's off again
mirabeau
03/9/2019
07:31
"...Given the performance in the period to date, the Board anticipates that the results for the full year ending 30 September 2019 will be materially ahead of current market expectations. Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are delighted to see continued momentum in our revenue growth, establishing 2019 as an inflexion point in the Company's progress. This is a fantastic achievement which reflects the Company's ability to support and grow with the increasing demand for our high quality neurological imaging and data analytics services."
someuwin
28/8/2019
12:23
Buyers grabbing the cheap stock.
someuwin
23/8/2019
08:48
Full interview: IXICO CFO Grant Nash joins board and discusses 'strong' 2019 performance IXICO PLC (LON:IXI) CFO Grant Nash says the firm's performance for the current year will be materially ahead of market expectations - benefitting from new and expanded contracts, the deployment of newly-developed algorithms and faster turnaround times in trial initiation. Nash, who was appointed to the role in April, has this week joined the board with immediate effect. https://www.proactiveinvestors.co.uk/companies/news/901400/ixico-cfo-grant-nash-joins-board-and-discusses--strong--2019-performance-901400.html
someuwin
23/8/2019
07:51
#IXICO #IXI Significant holders have over 71%
someuwin
22/8/2019
07:45
Snippet from the Simon Tmompson piece... "...The technology is proving incredibly popular. In fact, no fewer than eight of the 14 top 20 biopharmaceutical companies that have active neurological drug development programmes are clients of IXICO. They clearly hold the company in high esteem as IXICO has booked over £20m worth of new orders since the start of last year, a revenue stream that supports a sustained move to operating profitability. Once that inflexion point is passed, the high gross margin (62 per cent) earned from its cutting edge data analytics activities means that operating profits are set to move sharply higher in the years ahead given the significant amount of automation in the workflow and remote management of the clinical trial imaging sites. This means that IXICO is able to take on additional revenue generating activities without an equivalent increase in staffing costs, the effect of which is that any outperformance against revenue forecasts delivers a high conversion rate of incremental gross margin earned to operating profit. This operational leverage effect is also illustrated by the fact that over the past few years IXICO’s staffing levels have remained between 60 to 70 employees even though revenues earned have more than doubled since 2016."
someuwin
21/8/2019
13:57
Max buy now £1k.
someuwin
21/8/2019
11:45
Can currently buy £4K online - but not £5k
someuwin
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
IXI
Ixico
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191116 01:34:35